Zyngenia promotes David Hilbert and appoints Daniel Menichella
This article was originally published in Scrip
Zyngenia, a biopharmaceutical company developing the next generation of antibody-based drugs, has promoted Dr David Hilbert to CSO and appointed Daniel Menichella CBO. Dr Hilbert joined Zyngenia in October 2009 as vice-president of research and development. Mr Menichella was previously senior vice-president of corporate development and strategy at Talecris Biotherapeutics.